UNSPSC 51352005: Etonogestrel

This classification denotes a therapeutic progestin with the molecular formula C22H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 304GTH6RNH, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- but generally known as etonogestrel, which bears US NIH Compound Identifier 40976. European Medicines Agency schedules Etonogestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07335MIG.

UNSPSC 51352005 Etonogestrel, a Commodity code, encompasses contraceptive implants and related hormonal products that state and local health systems procure through cooperative purchasing vehicles and direct pharmaceutical supply agreements. The code captures individual pharmaceutical products sourced through generic multi-source procurement, where state agencies and their participating local partners negotiate pricing and supply terms with manufacturers and establish distribution channels via licensed pharmaceutical wholesalers. State health departments and their subordinate facilities—including correctional institutions, public health clinics, and safety-net hospitals—are the primary buying entities under this code, often working through established cooperative purchasing alliances rather than issuing individual solicitations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including contraceptive medications, with distribution across participating state and local government facilities in Minnesota and Oregon. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available by May 15, 2026 and awards effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent weight), compliance with cGMP and Drug Supply Chain Security Act requirements, EDI capability, and fixed pricing structures; vendors must maintain relationships with at least two authorized wholesalers and carry professional liability insurance of $2,000,000. No specific budget or award value is disclosed; however, awarded vendors pay a 3 percent administrative fee on all contract purchases and face performance penalties of $200 to $1,500 per violation.